Clozapine and blood dyscrasia

Psychiatrist

Volumn 35, Issue 1, 2011, Pages 27-29

  Latif, Zahid ^a,b   Jabbar, Faraz ^c   Kelly, Brendan D ^c  

^a St Anne's Day Hospital   (Ireland)

^b UNIVERSITY OF LIMERICK   (Ireland)

^c MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLOZAPINE; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; LIPID; LITHIUM; MAJOR HISTOCOMPATIBILITY ANTIGEN; NORCLOZAPINE; OLANZAPINE; PHENOTHIAZINE;

AGRANULOCYTOSIS; BLOOD DYSCRASIA; CARDIOVASCULAR DISEASE; CELL MATURATION; DISEASE PREDISPOSITION; DRUG METABOLISM; DRUG MONITORING; DRUG RECHALLENGE; EVIDENCE BASED MEDICINE; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LIPID BLOOD LEVEL; MYELOID PROGENITOR CELL; NEUTROPENIA; PATIENT MONITORING; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SEIZURE;

EID: 78651246965     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.109.026054     Document Type: Review

References (17)

1. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2009; 18; 39-60.
2. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
3. Pirmohamed M, Park K. Mechanism of clozapine-induced agranulocytosis. CNS Drugs 1997; 7: 139-158.
4. Gerson SL. Clozapine - deciphering the risks. N Engl J Med 1993; 329: 204-5.
5. Gerson SL. G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 1994; 55: 139-42.
6. Atkin K, Kendall F, Gould D, Freeman H, Lieberman J, O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 1996; 169: 483-8.
7. Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188: 255-63.
8. Munro J, O'Sullivan D, Andrews C, Arana A, Mortimer A, Kerwin R. Active monitoring of 12760 clozapine recipients in the UK and Ireland: beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576-80.
9. Kelly DL, Kreyenbuhl J, Dixon L, Love RC, Medoff D, Conley RR. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007; 33: 1221-4.
10. Williams DP, Pirmohamed M, Naisbitt DJ, Maggs JL, Park BK. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J Pharmacol Exp Ther 1997; 283: 1375-82.
11. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996; 312: 71-2.
12. Esposito D, Hardy P, Corruble E. Clozapine treatment following blood dyscrasia. Br J Psychiatry 2006; 189: 186.
13. Ghaznavi S, Nakic M, Rao P, Hu J, Brewer JA, Hannestad J, Bhagwagar Z. Rechallenge with clozapine following neutropenia: treatment options for refractory schizophrenia. Am J Psychiatry 2008; 165: 813-8.
14. Taylor D, Paton C, Kapur S. The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines (10th edn). Informa Healthcare, 2009.
15. Whiskey E, Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007; 21: 25-35.
16. Dernovsek Z, Tavcar R. Risperidone induced leucopenia and neutropenia. Br J Psychiatry 1997; 171: 393-4.
17. Thangadurai P, Jyothi KS, Gopalakrishnan R, Kuruvilla A, Jacob KS. Reversible neutropenia with olanzapine following clozapine-induced neutropenia. Am J Psychiatry 2006; 163: 1298.